基于公司全产业链优势和多板块协同效应，2024年东北制药经营质量稳步提升，发展底盘持续加固，实 现营业收入75.03亿元，实现归母净利润4.10亿元，同比增长14.34%；实现扣非净利润3.12亿元，同比增 长18.97%；公司经营活动产生的现金流量净额为7.59亿元，同比增长29.32%。 在持续巩固传统化学药业务的同时，东北制药敏锐捕捉到细胞治疗市场的新机遇，积极布局生物创新药 前沿领域，为公司未来长远发展奠定坚实基础。2024年通过对北京鼎成肽源生物技术有限公司(以下简 称"鼎成肽源")70%股权的收购，快速切入特异性细胞免疫治疗技术的研究、产品开发和临床应用业 务。 目前，鼎成肽源已构建TCR-T和CAR-T细胞治疗产品完整的技术平台及产品转化体系，针对胰腺癌、结 直肠癌、胃癌、肝癌和脑胶质瘤等疾病，开发了靶向KRAS突变、EGFRvIII、AFP和Claudin18.2等靶点 的TCR-T、TCR蛋白药和创新型CAR-T等10余款细胞治疗产品。其中，DCTY1102注射液已获得国家药 监局临床试验默示许可。东北制药相关负责人表示，公司对鼎成肽源的研发能力和潜在市场前景充满信 心，今年将加快推进相关研 ...

Core Viewpoint - The pharmaceutical industry in China is undergoing a deep adjustment period with intensified competition in the existing market. Northeast Pharmaceutical (000597) has demonstrated strong profitability and operational resilience despite the complex market environment, as evidenced by its financial performance in 2024 [1][2]. Financial Performance - In 2024, Northeast Pharmaceutical achieved a revenue of 7.503 billion yuan and a net profit attributable to shareholders of 410 million yuan, with year-on-year growth rates of 14.34% and 18.97% respectively. The net cash flow from operating activities was 759 million yuan, reflecting a year-on-year increase of 29.32% [1][2]. Operational Quality Improvement - The overall operational quality of Northeast Pharmaceutical has improved, with a significant reduction in total operating costs compared to the previous year. The sales of its main products continue to maintain strong competitiveness, leading to steady profit growth. The company leveraged its "raw material + formulation" integration advantage to enhance market competitiveness and increased export revenue by 26.30% year-on-year [2]. R&D Innovation - Northeast Pharmaceutical is actively investing in research and development to establish a solid foundation for long-term growth. The company focuses on both generic and innovative drugs, implementing a phased R&D management approach. In 2024, it successfully obtained one innovative drug candidate and received production approval for five generic drugs, while also advancing several new products towards market launch [3][4]. Strategic Acquisition - The company has strategically acquired a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., positioning itself in the emerging field of cell therapy. Dingcheng Peptide Source has developed a comprehensive technology platform for TCR-T and CAR-T cell therapy products targeting various cancers, with ongoing clinical trials for its products [4].

公司股份计划的进展情况暨权益变动的提示性公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1.本次权益变动为东北制药集团股份有限公司（以下简称"公司"）控股股 东一致行动人江西方大钢铁集团有限公司（以下简称"方大钢铁"或"控股股东 一致行动人"）履行此前已披露的增持股份计划，计划自增持股份计划披露之日 起 6 个月内增持公司股份，计划增持金额不少于人民币 7,500 万元,不超过人民 币 15,000 万元。方大钢铁承诺在增持计划实施期间，将遵守中国证监会、深圳证 券交易所关于上市公司股票买卖的相关规定，不进行内幕交易、敏感期交易及短 线交易等行为，在上述实施期限内完成增持计划，并且在增持期间、增持股份计 划完成后 6 个月内以及法律法规规定的期限内不减持公司股份。 证券代码：000597 证券简称：东北制药 公告编号：2025-033 详见公司于 2024 年 12 月 11 日披露的《东北制药集团股份有限公司关于控 股股东一致行动人增持公司股 ...

东北制药集团股份有限公司详式权益变动报告书 东北制药集团股份有限公司 详式权益变动报告书 | 上市公司 | 东北制药集团股份有限公司 | | --- | --- | | 上市地点 | 深圳证券交易所 | | 股票简称 | 东北制药 | | 股票代码 | 000597 | | 信息披露义务人名称 | 通讯地址 | | --- | --- | | 江西方大钢铁集团有限公司 | 江西省南昌市青山湖区东郊南钢路 | | 一致行动人名称 | 通讯地址 | | | | --- | --- | --- | --- | | 辽宁方大集团实业有限公司 | 北京市朝阳区霄云路甲 26 号海航大厦 | 25 | 层 | | 方威 | 北京市朝阳区霄云路甲 26 号海航大厦 | 25 | 层 | 股份变动性质：股份增加（集中竞价） 签署日期：二〇二五年四月 P A G E 东北制药集团股份有限公司详式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》（简称"公司法"）《中 华人民共和国证券法》（简称""证券法"）《上市公司收购管理办法》（简称""收购 办法"）《公开发行证券的公司信息披露内容与格式准则 ...

Core Viewpoint - Northeast Pharmaceutical (000597) announced that its controlling shareholder's concerted action party, Jiangxi Fangda Steel Group Co., Ltd., will increase its shareholding in the company by 1.5175 million shares from April 9 to April 15, 2025, representing 0.106% of the total share capital [1] Group 1 - After this increase, the controlling shareholder and its concerted action parties will hold a total of 786 million shares, accounting for 55.00% of the company's total share capital [1] - The share increase is supported by a special loan for stock repurchase and increase, amounting to RMB 108 million, with a loan term of 36 months and an interest rate of 2.25% [1]

● 本报记者 宋维东 提高经营质量 东北制药还持续强化产销衔接，落实降本控费指标，将精细化管理理念融入生产全流程；以工艺精控作 为核心切入点，全方位深入挖掘降本点并全力推进技术降本。此外，新增多家合格供应商，提高采购保 供能力和议价能力；采取灵活的采购策略，严控库存，在节约资金的同时防范市场下行风险，降低采购 成本。 一系列行之有效的举措推动公司整体经营质量不断提升。日前发布的年报显示，2024年，东北制药实现 营收75.03亿元，实现归母净利润约4.1亿元，实现扣非归母净利润3.12亿元。其中，归母净利润、扣非 归母净利润同比分别增长14.34%、18.97%，主营业务盈利能力持续增强。此外，公司经营活动产生的 现金流量净额为7.59亿元，较上年同期增长29.32%。 创新驱动增后劲 这些年来，东北制药持续加大新产品研发力度，坚持仿制药、创新药"双创新"驱动，实施"分步式"研发 节点管理，加速在研新产品项目研发进度，不断拓展生物创新药研发管线。 该负责人介绍，2024年，公司成功获得1个创新药候选分子，获批生产5个仿制药；非那西丁和恩格列净 完成CDE审评，获得原料药上市申请批准通知书；盐酸达泊西汀片(30 ...

核心提示 东北制药整肠生生产线。 受访单位供图 近日，辽宁方大集团东北制药发布2024年年报。2024年，公司实现营收75.03亿元，实现归母净利润4.1亿元，实现扣非净利润3.12亿元。其中，归母净利 润、扣非净利润同比分别增长14.34%、18.97%。此外，公司经营活动产生的现金流量净额为7.59亿元，同比增长29.32%。 2024年，东北制药凭借精准的战略布局和高效的执行能力，在市场拓展、成本管控、研发创新三大核心领域实现突破性进展，承压上扬构筑高质量发展格 局。 市场拓展 此外，积极推进生产现场新资源开发工作，全年新增多家合格供应商，提升采购保供能力和议价能力。通过科学分析研判上下游市场价格趋势，采取灵活的 采购策略，严格控制库存，在节约资金的同时防范市场下行风险，降低采购成本。 研发创新 "精仿+生物创新药"双创驱动谋未来 "全球布局+终端深耕"开拓增长新空间 受多重因素的持续影响，制药行业已进入深度调整期，存量市场竞争愈发激烈。东北制药通过"全球布局+终端深耕"双轮驱动，实现市场份额逆势提升。 向外看。2024年，东北制药实现海外销售收入9.02亿元，同比增长26.3%，毛利率水平也进一步得到 ...

Core Viewpoint - Northeast Pharmaceutical (000597) announced that its subsidiary, Shenyang First Pharmaceutical Co., Ltd., received the drug registration certificate from the National Medical Products Administration for Levetiracetam Extended-Release Tablets, which is approved for use in patients aged 12 and above for adjunctive treatment of partial seizures in epilepsy [1] Summary by Category - **Product Approval** - The drug name is Levetiracetam Extended-Release Tablets, with the approval number Guoyao Zhunzi H20253711, valid until March 24, 2030 [1] - The medication is specifically indicated for patients aged 12 years and older who experience partial seizures as part of their epilepsy treatment [1]

证券代码：000597 证券简称：东北制药 公告编号：2025-032 东北制药集团股份有限公司 关于子公司获得药品注册证书的公告 三、对公司的影响 本次获得左乙拉西坦缓释片《药品注册证书》，有利于进一步丰富公司产品 管线，提升公司的市场竞争力，带来新的市场机会。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，东北制药集团股份有限公司（以下简称"公司"）全资子公司东北制 药集团沈阳第一制药有限公司收到国家药品监督管理局核准签发的《药品注册证 书》（受理号：CYHS2301768，证书编号：2025S00826），现就相关情况公告如 下： 二、其他相关信息 左乙拉西坦是吡咯烷酮衍生物。体外、体内试验显示，左乙拉西坦可抑制海 1 药品名称 药品通用名称：左乙拉西坦缓释片 英文名/拉丁名：Levetiracetam Sustained-release Tablets 主要成分 左乙拉西坦 剂型 片剂 申请事项 药品注册（境内生产） 规格 0.5g 注册药品 分类 化学药品 3 类 药品注册 标准编号 YBH05382025 药品有效期 18 个月 包装规格 ...

Core Viewpoint - Northeast Pharmaceutical (SZ000597) reported a decrease in revenue for 2024, while net profit increased, indicating a mixed financial performance for the year [1]. Financial Performance - In 2024, Northeast Pharmaceutical achieved operating revenue of 7.50 billion yuan, a decrease of 8.98% compared to 2023 [2]. - The net profit attributable to shareholders was 409.85 million yuan, an increase of 14.34% year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 311.65 million yuan, up 18.97% from the previous year [2]. - The net cash flow from operating activities was 758.76 million yuan, reflecting a significant increase of 29.32% [2]. - Basic and diluted earnings per share were both 0.29 yuan, representing a 16.00% increase [2]. - The weighted average return on equity was 8.02%, up from 7.65% in 2023 [2]. Asset and Equity Position - Total assets at the end of 2024 were 14.45 billion yuan, down 5.42% from the previous year [2]. - The net assets attributable to shareholders increased to 5.32 billion yuan, a rise of 6.68% compared to 2023 [2]. Employee Statistics - As of the end of 2024, the total number of employees at Northeast Pharmaceutical was 5,964, a decrease of 250 employees or 4.02% from the previous year [2]. Executive Compensation - In 2024, three executives received salaries exceeding one million yuan, with the highest being 2.56 million yuan for the Deputy General Manager [4].